Silicon Valley’s gene-editor Synthego files for bankruptcy with plans to sell itself to lenders

By Steven Church, Bloomberg

Synthego Corp., which makes gene-editing tools for drug developers and other researchers, filed for bankruptcy with plans to sell itself to its main lender, an affiliate of private equity firm Perceptive Advisors.

Related Articles

• How AI and tech are streamlining recovery in the footprint of Southern California wildfires
• Nvidia South Bay buying binge tops $700 million with new property buys...